Truist Financial Has Lowered Expectations for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH) had its price objective reduced by equities research analysts at Truist Financial from $127.00 to $117.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price objective would indicate a potential upside of 42.93% from the company’s current price.

Several other equities research analysts also recently issued reports on LNTH. B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. JMP Securities reiterated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $132.67.

Lantheus Stock Up 1.8 %

LNTH opened at $81.86 on Thursday. The stock has a market cap of $5.61 billion, a P/E ratio of 13.62 and a beta of 0.23. Lantheus has a 12 month low of $75.00 and a 12 month high of $126.89. The company has a fifty day simple moving average of $99.57 and a 200 day simple moving average of $94.36.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same quarter last year, the company earned $1.69 earnings per share. The firm’s revenue was up .8% compared to the same quarter last year. On average, equities research analysts expect that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 in the last three months. Insiders own 2.00% of the company’s stock.

Institutional Trading of Lantheus

A number of large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in shares of Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the period. Farallon Capital Management LLC raised its stake in Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after buying an additional 2,361,000 shares during the period. TD Asset Management Inc raised its stake in Lantheus by 1,028.0% in the first quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock valued at $66,623,000 after buying an additional 622,100 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after buying an additional 435,445 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Lantheus during the 4th quarter worth approximately $36,183,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.